JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Home・Lista de Ações・Fate Therapeutics Inc

Fate Therapeutics Inc

Fechado

SetorSaúde

1.64 8.61

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.63

Máximo

1.6600000000000001

Indicadores-chave
By Trading Economics
Rendimento	3.6M -34M
Vendas	278K 1.9M
Margem de lucro	-1,786.576
Funcionários	181
EBITDA	979K -37M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+147.27% upside

Dividendos
By Dow Jones
Próximos Ganhos	10 de nov. de 2025

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	70M 178M
Abertura anterior	-6.97
Fecho anterior	1.64

Sentimento de Notícias

By Acuity

50%

147 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

0.9101 / 1.14 Suporte e Resistência

Fate Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de out. de 2025, 18:41 UTC

Ganhos

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 de out. de 2025, 18:31 UTC

Ganhos

Correction to Procter & Gamble to Focus on Innovation

24 de out. de 2025, 16:25 UTC

Grandes Movimentos do Mercado

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 de out. de 2025, 21:24 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 de out. de 2025, 21:24 UTC

Conversa de Mercado

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 de out. de 2025, 21:07 UTC

Ganhos

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 de out. de 2025, 20:58 UTC

Ganhos

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 de out. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

24 de out. de 2025, 20:40 UTC

Ganhos

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 de out. de 2025, 20:24 UTC

Ganhos

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 de out. de 2025, 20:23 UTC

Ganhos

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 de out. de 2025, 20:13 UTC

Ganhos

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 20:07 UTC

Conversa de Mercado

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 de out. de 2025, 19:40 UTC

Conversa de Mercado

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 de out. de 2025, 19:35 UTC

Conversa de Mercado

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 de out. de 2025, 19:33 UTC

Ganhos

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 de out. de 2025, 19:29 UTC

Conversa de Mercado

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 de out. de 2025, 18:52 UTC

Ganhos

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 de out. de 2025, 18:41 UTC

Ganhos

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 de out. de 2025, 18:03 UTC

Ganhos

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 de out. de 2025, 18:02 UTC

Ganhos

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 de out. de 2025, 18:00 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 de out. de 2025, 16:57 UTC

Ganhos

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 de out. de 2025, 16:54 UTC

Conversa de Mercado

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 de out. de 2025, 16:44 UTC

Conversa de Mercado

Ganhos

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 de out. de 2025, 16:39 UTC

Conversa de Mercado

Ganhos

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 de out. de 2025, 16:33 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 16:23 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

24 de out. de 2025, 16:07 UTC

Ganhos

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Comparação entre Pares

Variação de preço

Fate Therapeutics Inc Previsão

Preço-alvo

By TipRanks

147.27% parte superior

Previsão para 12 meses

Média 4.08 USD 147.27%

Máximo 7 USD

Mínimo 2 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Fate Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Fate Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

0.9101 / 1.14Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentimento

By Acuity

147 / 371 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.